DK3407889T3 - Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet - Google Patents
Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet Download PDFInfo
- Publication number
- DK3407889T3 DK3407889T3 DK17771285.8T DK17771285T DK3407889T3 DK 3407889 T3 DK3407889 T3 DK 3407889T3 DK 17771285 T DK17771285 T DK 17771285T DK 3407889 T3 DK3407889 T3 DK 3407889T3
- Authority
- DK
- Denmark
- Prior art keywords
- prevention
- treatment
- organic compounds
- central nervous
- nervous diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313629P | 2016-03-25 | 2016-03-25 | |
| PCT/US2017/024137 WO2017165843A1 (en) | 2016-03-25 | 2017-03-24 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3407889T3 true DK3407889T3 (da) | 2021-08-09 |
Family
ID=59900860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17771285.8T DK3407889T3 (da) | 2016-03-25 | 2017-03-24 | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US10688097B2 (da) |
| EP (2) | EP3407889B1 (da) |
| JP (5) | JP6686168B2 (da) |
| KR (2) | KR102684468B1 (da) |
| CN (2) | CN113754661A (da) |
| AU (1) | AU2017238842B2 (da) |
| BR (1) | BR112018069594B1 (da) |
| CA (1) | CA3016353C (da) |
| DK (1) | DK3407889T3 (da) |
| ES (1) | ES2879888T3 (da) |
| HU (1) | HUE055334T2 (da) |
| IL (5) | IL281050B2 (da) |
| MX (2) | MX387700B (da) |
| PL (1) | PL3407889T3 (da) |
| PT (1) | PT3407889T (da) |
| RU (1) | RU2733975C2 (da) |
| SI (1) | SI3407889T1 (da) |
| WO (1) | WO2017165843A1 (da) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| AU2013245702A1 (en) | 2012-04-14 | 2014-11-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015085004A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20170012210A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| DK3407889T3 (da) * | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018175969A1 (en) * | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| CA3071137A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| JP2020535231A (ja) | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規な塩および結晶 |
| US11980617B2 (en) | 2018-03-16 | 2024-05-14 | Intra-Cellular Therapies, Inc. | Methods of treating acute depression and/or acute anxiety |
| CN112088004A (zh) * | 2018-03-23 | 2020-12-15 | 细胞内治疗公司 | 有机化合物 |
| WO2019183341A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2020013116A (es) | 2018-06-06 | 2021-05-12 | Intra Cellular Therapies Inc | Sales y cristales novedosos. |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP7483671B2 (ja) * | 2018-06-11 | 2024-05-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ－カルボリン類合成 |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| AU2019331490B2 (en) | 2018-08-31 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP7546546B2 (ja) | 2018-08-31 | 2024-09-06 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| WO2020131911A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| CA3121631A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| JP7487204B2 (ja) * | 2018-12-17 | 2024-05-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2020132474A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compound |
| JP7649743B2 (ja) | 2018-12-21 | 2025-03-21 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| EP4134101A1 (en) | 2019-07-07 | 2023-02-15 | Intra-Cellular Therapies, Inc. | Deuterated lumateperone for the treatment of the bipolar ii disorder |
| US12478623B2 (en) | 2019-09-25 | 2025-11-25 | Intra-Cellular Therapies, Inc. | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor |
| JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2022051770A2 (en) * | 2020-09-04 | 2022-03-10 | Intra-Cellular Therapies, Inc. | Novel salts, crystals, and co-crystals |
| AU2023272111A1 (en) | 2022-05-18 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| EP4642458A1 (en) | 2022-12-30 | 2025-11-05 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor |
| CN121152625A (zh) | 2023-02-17 | 2025-12-16 | 细胞内治疗公司 | 用于调节神经系统的卢美哌隆和其衍生物 |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
| WO2025257090A1 (en) | 2024-06-10 | 2025-12-18 | Interquim, S.A. | Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4136145A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| US4155577A (en) | 1978-06-12 | 1979-05-22 | Raymond Edward L | Security device |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS6067524A (ja) | 1983-09-22 | 1985-04-17 | Mitui Toatsu Chem Inc | 超軟質ポリウレタンエラストマ−の耐熱性改良方法 |
| JPS63501794A (ja) | 1985-10-09 | 1988-07-21 | デジテイン アルツナイミツテル ゲ−エムベ−ハ− | 医薬有効物質，試薬，その他の作用物質の提供ないし投与形態の製造法 |
| ZA871987B (en) | 1986-03-19 | 1988-05-25 | Kumiai Chemical Industry Co | 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same |
| ES2058069T3 (es) | 1986-04-07 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado. |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| DE4018247A1 (de) | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| HU219487B (hu) | 1993-11-19 | 2001-04-28 | Janssen Pharmaceutica Nv. | Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk |
| US5763476A (en) | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CA2186371A1 (en) | 1994-03-25 | 1995-10-05 | Robert T. Foster | Enhancement of the efficacy of dihydropyridines by deuteration |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6884429B2 (en) | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
| US6395939B1 (en) | 1997-10-06 | 2002-05-28 | Massachusetts Institute Of Technology | Diaryl ether condensation reactions |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| JP4647780B2 (ja) | 1998-02-26 | 2011-03-09 | マサチューセッツ インスティテュート オブ テクノロジー | ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化 |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| DE69935933T2 (de) | 1998-07-10 | 2008-01-10 | Massachusetts Institute Of Technology, Cambridge | Liganden für Metalle und verbesserte Metall-katalysierte Verfahren, die darauf basieren |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| CN1161101C (zh) | 1998-12-17 | 2004-08-11 | 阿尔扎有限公司 | 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统 |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| NO309305B1 (no) | 1999-02-19 | 2001-01-15 | Norsk Hydro As | Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater |
| US6376426B1 (en) | 1999-04-23 | 2002-04-23 | Basf Aktiengesellschaft | Herbicidal 3-(heterocycl-1-yl)-uracils |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| HK1043112A1 (zh) | 1999-06-15 | 2002-09-06 | Bristol-Myers Squibb Pharma Company | 取代的稠杂环γ-咔啉 |
| PT1104760E (pt) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| HUP0303432A3 (en) | 2000-12-20 | 2012-09-28 | Bristol Myers Squibb Co | Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| DK1245884T3 (da) | 2001-03-26 | 2005-08-29 | Hawle Armaturen Gmbh | Væggennemföringssystem |
| EP1390340B1 (en) | 2001-04-24 | 2017-03-01 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| DE10123129A1 (de) | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| WO2003014118A1 (en) | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| EP1314554A1 (fr) | 2001-11-23 | 2003-05-28 | Kba-Giori S.A. | Dispositif de décollage d'éléments de sécurité |
| DE10162121A1 (de) | 2001-12-12 | 2003-06-18 | Berolina Drug Dev Ab Svedala | Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| JP4500679B2 (ja) | 2002-07-29 | 2010-07-14 | アルザ・コーポレーシヨン | パリペリドンを制御送達する方法および投薬形態物 |
| US6888032B2 (en) | 2002-08-02 | 2005-05-03 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| US20040142970A1 (en) | 2002-11-01 | 2004-07-22 | Kathryn Chung | Treatment of hyperkinetic movement disorder with donepezil |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| ES2364046T3 (es) | 2002-12-19 | 2011-08-23 | Bristol-Myers Squibb Company | Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina. |
| CN1852893A (zh) | 2003-07-21 | 2006-10-25 | 史密丝克莱恩比彻姆公司 | (2S,4S)－4－氟－1－[4－氟－β－(4－氟苯基)－L－苯基丙氨酰基]－2－吡咯烷甲腈对甲苯磺酸盐及其无水晶体形式 |
| TW200514785A (en) | 2003-09-26 | 2005-05-01 | Solvay Pharm Bv | Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| EP1756102A1 (en) | 2004-03-05 | 2007-02-28 | Pharma C S.A. | 8-PHENOXY-GammaCARBOLINE DERIVATIVES |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| WO2006034187A2 (en) | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| WO2006032999A1 (en) | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-methyl hydroxyethylamine useful in treating cns conditions |
| US7614727B2 (en) | 2004-09-30 | 2009-11-10 | Fujifilm Corporation | Liquid ejection head, manufacturing method thereof, and image forming apparatus |
| MX2007006896A (es) | 2004-12-15 | 2007-06-26 | Hoffmann La Roche | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
| KR20070099031A (ko) | 2005-01-25 | 2007-10-08 | 셀진 코포레이션 | 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물 |
| US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
| CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| JP2009523734A (ja) | 2006-01-13 | 2009-06-25 | ワイス | ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| WO2009017836A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| NO2180844T3 (da) | 2007-08-02 | 2018-07-21 | ||
| EP2190844B3 (en) | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| US20090209608A1 (en) | 2007-08-29 | 2009-08-20 | Protia, Llc | Deuterium-enriched asenapine |
| US20090076159A1 (en) | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched eplivanserin |
| EP2262502A4 (en) | 2008-02-05 | 2011-12-28 | Clera Inc | Compositions and methods for alleviating depression or improving cognition |
| MX2010010024A (es) | 2008-03-12 | 2010-11-09 | Intra Cellular Therapies Inc | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
| AU2009251816B2 (en) | 2008-05-27 | 2015-12-10 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
| US20100159033A1 (en) | 2008-09-29 | 2010-06-24 | Auspex Pharmaceuticals, Inc. | Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor |
| JP5989993B2 (ja) * | 2008-12-06 | 2016-09-07 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| US8778893B2 (en) | 2009-10-05 | 2014-07-15 | Bristol-Myers Squibb Company | (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol metabolites |
| CN103209704B (zh) | 2010-04-22 | 2017-10-27 | 细胞内治疗公司 | 有机化合物 |
| ES2791715T3 (es) | 2010-12-16 | 2020-11-05 | Sunovion Pharmaceuticals Inc | Películas sublinguales |
| US8697700B2 (en) | 2010-12-21 | 2014-04-15 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof |
| US8420057B2 (en) | 2011-09-01 | 2013-04-16 | Qualicaps, Inc. | Capsule having broad color spectrum |
| AU2013245702A1 (en) | 2012-04-14 | 2014-11-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AR092568A1 (es) | 2012-09-14 | 2015-04-22 | Abbvie Deutschland | Derivados triciclicos de quinolinas y de quinoxalinas |
| WO2014110322A2 (en) * | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| DK3043777T3 (da) | 2013-09-10 | 2020-07-20 | Fresh Cut Dev Llc | Sublingual buprenorphinspray |
| US10350196B2 (en) | 2013-09-30 | 2019-07-16 | Zoetis Services Llc | Long-acting spiro-isoxazoline formulations |
| WO2015085004A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20170012210A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| HUE047855T2 (hu) | 2015-05-12 | 2020-05-28 | Taiho Pharmaceutical Co Ltd | 3-etil-4-{3-izopropil-4-(4-(1-metil-1H-pirazol-4-il)-1H-imidazol-1-il)-1H-pirazolo[3,4-B|piridin-1-il}benzamid kristály alakja |
| EP4512394A3 (en) | 2015-06-03 | 2025-10-22 | Triastek, Inc. | Dosage forms and use thereof |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| DK3407889T3 (da) * | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| US20200392135A1 (en) | 2016-03-25 | 2020-12-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018106916A1 (en) * | 2016-12-07 | 2018-06-14 | Concert Pharmaceuticals, Inc. | Deuterated quinoxaline compounds |
| WO2018175969A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| US11292793B2 (en) | 2017-04-10 | 2022-04-05 | Dr. Reddy's Laboratories Limited | Solid dispersions of amorphous Lumateperone p-Tosylate |
| CN111093665A (zh) | 2017-07-26 | 2020-05-01 | 细胞内治疗公司 | 有机化合物 |
| CA3071137A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| WO2019183341A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
-
2017
- 2017-03-24 DK DK17771285.8T patent/DK3407889T3/da active
- 2017-03-24 EP EP17771285.8A patent/EP3407889B1/en active Active
- 2017-03-24 SI SI201730872T patent/SI3407889T1/sl unknown
- 2017-03-24 AU AU2017238842A patent/AU2017238842B2/en active Active
- 2017-03-24 RU RU2018137496A patent/RU2733975C2/ru active
- 2017-03-24 JP JP2018549879A patent/JP6686168B2/ja active Active
- 2017-03-24 IL IL281050A patent/IL281050B2/en unknown
- 2017-03-24 IL IL297676A patent/IL297676B2/en unknown
- 2017-03-24 KR KR1020227045681A patent/KR102684468B1/ko active Active
- 2017-03-24 EP EP21172297.0A patent/EP3888656A1/en active Pending
- 2017-03-24 US US16/088,397 patent/US10688097B2/en active Active
- 2017-03-24 IL IL304192A patent/IL304192B2/en unknown
- 2017-03-24 BR BR112018069594-7A patent/BR112018069594B1/pt active IP Right Grant
- 2017-03-24 PL PL17771285T patent/PL3407889T3/pl unknown
- 2017-03-24 KR KR1020187030778A patent/KR102483124B1/ko active Active
- 2017-03-24 IL IL314312A patent/IL314312A/en unknown
- 2017-03-24 PT PT177712858T patent/PT3407889T/pt unknown
- 2017-03-24 ES ES17771285T patent/ES2879888T3/es active Active
- 2017-03-24 CN CN202111089807.3A patent/CN113754661A/zh active Pending
- 2017-03-24 HU HUE17771285A patent/HUE055334T2/hu unknown
- 2017-03-24 MX MX2018011676A patent/MX387700B/es unknown
- 2017-03-24 CA CA3016353A patent/CA3016353C/en active Active
- 2017-03-24 CN CN201780017040.9A patent/CN108778277A/zh active Pending
- 2017-03-24 WO PCT/US2017/024137 patent/WO2017165843A1/en not_active Ceased
-
2018
- 2018-08-29 IL IL261446A patent/IL261446B/en active IP Right Grant
- 2018-09-25 MX MX2021013564A patent/MX2021013564A/es unknown
-
2020
- 2020-04-01 JP JP2020065667A patent/JP6860724B2/ja active Active
- 2020-05-15 US US16/875,432 patent/US11096944B2/en active Active
-
2021
- 2021-03-26 JP JP2021053242A patent/JP7195362B2/ja active Active
- 2021-07-19 US US17/379,399 patent/US11723909B2/en active Active
-
2022
- 2022-12-13 JP JP2022198595A patent/JP7404491B2/ja active Active
-
2023
- 2023-06-22 US US18/339,956 patent/US12194044B2/en active Active
- 2023-12-13 JP JP2023209849A patent/JP2024037860A/ja active Pending
-
2024
- 2024-11-26 US US18/960,359 patent/US20250099471A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3407889T3 (da) | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3717471T3 (da) | Nye forbindelser og lægemiddelsammensætninger heraf til behandling af sygdomme | |
| DK3728271T3 (da) | Makrocykliske forbindelser til behandling af sygdomme | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3478679T3 (da) | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3340981T3 (da) | Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3777855T3 (da) | Fremgangsmåder til behandling af fibrotiske sygdomme | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3157522T3 (da) | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste |